VACC Stock Overview
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vaccitech plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.50 |
| 52 Week High | US$7.45 |
| 52 Week Low | US$2.02 |
| Beta | 0.17 |
| 1 Month Change | 6.84% |
| 3 Month Change | -15.25% |
| 1 Year Change | -42.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -82.27% |
Recent News & Updates
Recent updates
Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality
Nov 17
Vaccitech promotes Gemma Brown to CFO
Sep 20Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts
Aug 15Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Aug 13Vaccitech GAAP EPS of $0.41, revenue of $17.06M
Aug 09Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%
May 19Vaccitech: Aiming For A Cure In Chronic Hepatitis B
Apr 03Vaccitech: The Next Big Vaccine Trade
Jun 27Vaccitech EPS misses by $0.69, beats on revenue
Jun 14Shareholder Returns
| VACC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.8% | 2.3% | 2.5% |
| 1Y | -42.1% | 11.1% | 1.3% |
Return vs Industry: VACC underperformed the US Biotechs industry which returned 11.1% over the past year.
Return vs Market: VACC underperformed the US Market which returned 1.3% over the past year.
Price Volatility
| VACC volatility | |
|---|---|
| VACC Average Weekly Movement | 12.1% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VACC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: VACC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 33 | Bill Enright | https://www.vaccitech.co.uk |
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company’s therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection.
Vaccitech plc Fundamentals Summary
| VACC fundamental statistics | |
|---|---|
| Market Cap | US$94.39m |
| Earnings (TTM) | -US$15.43m |
| Revenue (TTM) | US$30.15m |
3.2x
P/S Ratio-6.2x
P/E RatioIs VACC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VACC income statement (TTM) | |
|---|---|
| Revenue | US$30.15m |
| Cost of Revenue | US$41.46m |
| Gross Profit | -US$11.31m |
| Other Expenses | US$4.12m |
| Earnings | -US$15.43m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -37.51% |
| Net Profit Margin | -51.19% |
| Debt/Equity Ratio | 0% |
How did VACC perform over the long term?
See historical performance and comparison